Newcells Biotech

Newcells Biotech Limited specializes in creating innovative in vitro tissue models to support pharmaceutical research.2 million.Newcells Biotech specializes in developing advanced in vitro tissue models that closely mimic human physiology, aimed at improving drug discovery and clinical translation. Their core offerings include retinal organoids and pigmented epithelium models for studying retinopathies, as well as proximal tubule models for renal toxicity evaluations. These products provide predictive data for drug efficacy and safety, targeting applications such as disease modeling, drug interactions, and therapeutic assessments. The company primarily serves pharmaceutical and biotechnology companies, research institutions, and academic organizations across global markets, including Europe, North America, and Asia.The revenue model for Newcells Biotech is structured around service contracts and partnerships with clients in the pharmaceutical and biotechnology sectors. The company engages in B2B transactions, where clients commission studies utilizing Newcells’ in vitro models for drug development purposes. Their offerings include tailored efficacy and safety testing services, alongside products that facilitate in-house testing. Revenue is generated through these contractual agreements, comprising both one-time fees for specific studies and ongoing partnerships for continuous research support. The company plans to expand its offerings with new products designed to enhance their in vitro models. Additionally, Newcells aims to penetrate new markets, specifically targeting regions in Europe and North America by the end of 2025.

1. Seed

   Aug 17, 2015

   Amount

   $0.2M

   Investors

   Locked